A Phase I Study of Duvelisib in Combination with CC-486 in Lymphoid Malignancy
The purpose of the study is to find a safe dose and to evaluate the safety and tolerability of the drug CC-486, in combination with duvelisib.
1. To evaluate the safety and dose limiting toxicity of the combination of PI3K inhibitor (Duvelisib) with hypomethylating agent (CC-486) in patients with lymphoid malignancy; 2. To evaluate the overall response rate to the treatment with combination therapy; 3. To evaluate the disease control rate of the combination; 4. To evaluate the progression free survival and overall survival in patients treated with the combination therapy. Exploratory Objectives: 1. To evaluate the changes in different T cells subpopulation in response to PI3K inhibition and hypomethylation 2. To evaluate the changes in pAKT in response to single agent Duvelisib in comparison to combination Duvelisib and CC-486
CC-486 (Azacitidine (Oral)); Duvelisib ()
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.